Non-surgical therapy of Peyronie's disease

Asian Journal of Andrology

Volumn 10, Issue 1, 2008, Pages 79-87

  Taylor, Frederick L ^a   Levine, Laurence A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amino acids; Humans; Injection sintralesional; Penile induration; Pentoxifylline; Peyronie's disease; Vitamin E

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; AMINOBENZOIC ACID; ARGININE; CARNITINE; COLCHICINE; COLLAGENASE; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; IBUPROFEN; LEVACECARNINE; PENTOXIFYLLINE; PLACEBO; STEROID; TAMOXIFEN CITRATE; TRIAMCINOLONE; VERAPAMIL;

ALOPECIA; APLASTIC ANEMIA; ATROPHY; CLINICAL TRIAL; DEVICE; DIARRHEA; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ELECTROSTIMULATION THERAPY; ENERGY; FIBROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE DEFICIENCY; IONTOPHORESIS; MONOTHERAPY; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PEYRONIE DISEASE; REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ARGININE; CARNITINE; COLLAGENASES; COMBINED MODALITY THERAPY; ELECTRIC STIMULATION THERAPY; HUMANS; MALE; PENILE INDURATION; PENTOXIFYLLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRACTION;

EID: 37749001177     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00351.x     Document Type: Review

References (70)

1. De La Peyronie F. Sur quelques obstaclesqui sópposent àl'éjaculation nautrelle de la semence. Mem Acad Royale Chir 1743; 1: 337-42.
2. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's like condition associated with an increase of transforming growth factor β mRNA and protein expression. J Urol 1997; 158: 2284-90.
3. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-4.
4. Bivalacqua TJ, Champion HC, Leungwattanakij S, Yang DY, Hyun JS, Abdel-Mageed AB, et al. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's like condition in the rat. J Androl 2001; 22: 497-506.
5. Kucharewicz I, Kowal K, Buczko W, Bodzenta-Lukaszyk A. The plasmin system in airway remodeling. Thromb Res 2003; 112: 1-7.
6. Van de Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: Implications for Peyronie's disease. J Urol 1997; 157: 306-10.
7. Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease is associated with an increase of plasminogen activator inhibitor-1 in fibrotic plaque. Urology 2005; 65: 645-8.
8. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: A new animal model of Peyronie's disease. BJU Int 2003; 91: 830-8.
9. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
10. Ryu JK, Piao S, Shin HY, Zhang L, Jin H, Han JY, et al. IN-1130, A novel transforming growth factory type 1 receptor kinase (ALK 5) inhibitor regresses fibrotic plaque and corrects penile curvature in a rat model of Peyronie's Disease. Annual Meeting of the American Urological Association, 2007, May 19-24, 2007, Anaheim, California, USA. Abstract 749.
11. Del Carlo M, Levine LA, Cole AA. Differential regulation of matrix metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinases (TIMPs) by interleukin-1 β (IL-1 β) and transforming growth factor β (TGF-β in Peyronie's fibroblasts. Annual Meeting of the American Urological Association, 2007, May 19-24, 2007, Anaheim, California, USA. J Urol 2007; 177 (4 Suppl): Abstract 755.
12. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004; 64: 399-404.
13. Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007; 4: 485-90.
14. Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol 1970; 103: 75-6.
15. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376-9.
16. Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP. A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 1075-9.
17. Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948; 41: 173-7.
18. Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002; 14: 353-60.
19. Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie's disease: A review. J Urol 2002; 169: 1234-41.
20. Pryor JP, Farell CF. Controlled clinical trial of vitamin E in Peyronie's Disease. Prog Reprod Biol 1983; 9: 41-5.
21. Furst DE, Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout. In: Basic and Clinical Pharmacology. Bertram G, editor. Katzung Lange: New York; 2001.
22. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease?A pilot study. Urology 1994; 44: 291-5.
23. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: Long term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169-75.
24. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study. Int J Impot Res 2004; 16: 238-43.
25. Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol 1959; 81: 770-2.
26. Hasche-Klunder R. Treatment of Peyronie's disease with para-aminobenzoacidic potassium (Potoba) (author's translation). Urologe A 1978; 17: 224-7.
27. Weidner W, Schroeder-Printzen I, Rudnick J. Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J Urol 1999; 6: 205.
28. Weidner W, Hauck EW, Schnitker J. Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530-6.
29. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648-51.
30. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405-9.
31. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003-5.
32. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 2001; 88: 63-7.
33. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229-44.
34. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3: 111-5.
35. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168: 2483-5.
36. Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HC1, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease -a placebo-controlled pilot study. J Sex Med 2007; 4: 477-84.
37. Levine LA. Comment on: Topical verpamil HC1, topical trfluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease -a placebo-controlled pilot study. J Sex Med 2007; 4: 1081-2.
38. Bodner H, Howard AH, Kaplan JH. Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 1954; 400-3.
39. Winter CC, Khanna R. Peyronie's disease: Results with dermojet injection of dexamethasone. J Urol 1975; 114: 898-900.
40. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol 1980; 52: 392-5.
41. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982; 10: 135-40.
42. Gelbard MK, Linkner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 280-3.
43. Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. placebo in the treatment of Peyronie's disease: A double blind study. J Urol 1993; 149: 56-8.
44. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478-82.
45. Mulhall J P, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397-405.
46. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522-4.
47. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long term single-blind study. Urology 1998; 51: 620-6.
48. Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie's disease: A review. Int J Impot Res 2002; 14: 324-8.
49. Bennett NE, Guhring, P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's Disease. Urology 2007; 69: 1181-4.
50. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89-94.
51. Wegner HE, Andreson R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha-2b. Eur Urol 1995; 28: 236-40.
52. Wegner HE, Andresen R, Knipsel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32: 190-3.
53. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999; 20: 444-8.
54. Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease. South Med J 2004; 97: 42-6.
55. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394-8.
56. Levine LA. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003; 15: S113-20.
57. Hauck EW, Altinkilic BM, Ludwig M, Ludecke G, Schroeder-Printzen I, Arens C, et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 2000; 38: 663-70.
58. Hatzichristodoulou G, Meisner C, Liske P, Stenzl A, Lahm S. Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie's disease (PD)-first results of a prospective, randomized, placebo-controlled, single-blind study. American Urological Association 2006 Annual Meeting. May 20-25, 2006, Atlanta, Georgia, USA. J Urol 2006; 175 (4 Suppl): Abstract 993.
59. Hatzichristodoulou G, Meisner C, Stenzyl A, Lahm S. Efficacy of extracorporeal shock wave therapy on plaque size and sexual function in patients with Peyronie's Disease -results of a prospective, randomized, placebo-controlled study. Annual Meeting of the American Urological Association, 2007, May 19-24, 2007, Anaheim, California, USA. J Urol 2007; 177 (4 Suppl): Abstract 747.
60. Riedl CR, Plas E, Engelhard P, Daha K, Pfluger H. Lontophoresis for treatment of Peyronie's disease. J Urol 2000; 163: 95-9.
61. Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M. Transdermal electromotive multi-drug administration for Peyronie's disease: Preliminary results. J Androl 2000; 21: 85-90.
62. Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Virgili G, Storti L, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003; 91: 825-9.
63. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Glurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004; 171: 1605-8.
64. Levine LA, Estrada CR, Show W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169: 1775-8.
65. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration (EDMA) for Peyronie's disease: A double blind, placebo controlled trial. J Urol 2007; 177: 972-5.
66. Ojingwa JC, Isseroff RR. Electrical stimulation of wound healing. J Invest Dermatol 2003; 121: 1-12.
67. Preito Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicines in the early stages of Peyronie's disease. BJU Int 2003; 91: 522-4.
68. Mirone V, Palmieri A, Granata AM, Piscopo A, Verze P, Ranavolo R. Ultrasound-guided ESWT in Peyronie's disease plaques. Arch Ital Urol Androl 2000; 72: 384-7.
69. Mirone V, Imbimbo C, Palmieri A, Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induration penis plastica. Eur Urol 1999; 36: 327-30.
70. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89: 895-900.